{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:18:34Z","timestamp":1792693114896,"version":"4.5.0"},"reference-count":168,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Comprehensive care integrates individual patient needs and is highly valued for patients with pulmonary fibrosis (PF). The importance of a patient-centered care approach is rooted in the unpredictable progressiveness of the disease course in PF. The respiratory impairment associated with PF has a major impact on the quality of life for both patients and their caregivers. We believe that prioritizing patient preferences could improve the shared decision making process and may ultimately lead to better health outcomes. Despite the growing emphasis for this approach, it remains challenging to adopt it in clinical practice. In this review, we propose the comprehensive Triple A Care Model, consisting of the domains Access, Anticipate, and Act, which emphasizes core elements of patient-centered care for patients with PF. We will provide an overview of the unmet needs in care for patients with PF and elaborate on the current methods for delivering patient-centered care. The latest insights into symptom management and supportive measures and several approaches to improving access to care are discussed, in line with the most recent guidelines.<\/jats:p>","DOI":"10.1186\/s12931-024-02997-7","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T18:02:23Z","timestamp":1730484143000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Patient-centered care in pulmonary fibrosis: access, anticipate, and act"],"prefix":"10.1186","volume":"25","author":[{"given":"Delian E.","family":"Hofman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonia","family":"Magr\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina C.","family":"Moor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Richeldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies S.","family":"Wijsenbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Waseda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"issue":"10","key":"2997_CR1","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMra2005230","volume":"383","author":"M Wijsenbeek","year":"2020","unstructured":"Wijsenbeek M, Cottin V. Spectrum of Fibrotic Lung diseases. N Engl J Med. 2020;383(10):958\u201368.","journal-title":"N Engl J Med"},{"issue":"9","key":"2997_CR2","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18\u201347.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2997_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12931-021-01791-z","volume":"22","author":"TM Maher","year":"2021","unstructured":"Maher TM, Bendstrup E, Dron L, Langley J, Smith G, Khalid JM, et al. Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res. 2021;22(1):197.","journal-title":"Respir Res"},{"issue":"1","key":"2997_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12931-019-1020-3","volume":"20","author":"M Kreuter","year":"2019","unstructured":"Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, et al. The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry. Respir Res. 2019;20(1):59.","journal-title":"Respir Res"},{"issue":"4","key":"2997_CR5","doi-asserted-by":"publisher","first-page":"2102571","DOI":"10.1183\/13993003.02571-2021","volume":"60","author":"N Hambly","year":"2022","unstructured":"Hambly N, Farooqi MM, Dvorkin-Gheva A, Donohoe K, Garlick K, Scallan C, et al. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. Eur Respir J. 2022;60(4):2102571.","journal-title":"Eur Respir J"},{"issue":"22","key":"2997_CR6","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr","year":"2014","unstructured":"King TE Jr., Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083\u201392.","journal-title":"N Engl J Med"},{"issue":"22","key":"2997_CR7","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071\u201382.","journal-title":"N Engl J Med"},{"issue":"26","key":"2997_CR8","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis-Associated interstitial lung disease. N Engl J Med. 2019;380(26):2518\u201328.","journal-title":"N Engl J Med"},{"issue":"6","key":"2997_CR9","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1136\/thoraxjnl-2016-209701","volume":"73","author":"L Richeldi","year":"2018","unstructured":"Richeldi L, Kreuter M, Selman M, Crestani B, Kirsten AM, Wuyts WA, et al. Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension. Thorax. 2018;73(6):581\u20133.","journal-title":"Thorax"},{"issue":"12","key":"2997_CR10","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","volume":"365","author":"L Richeldi","year":"2011","unstructured":"Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079\u201387.","journal-title":"N Engl J Med"},{"key":"2997_CR11","doi-asserted-by":"crossref","unstructured":"Lee JYT, Tikellis G, Corte TJ, Goh NS, Keir GJ, Spencer L et al. The supportive care needs of people living with pulmonary fibrosis and their caregivers: a systematic review. Eur Respir Rev. 2020;29(156).","DOI":"10.1183\/16000617.0125-2019"},{"issue":"2","key":"2997_CR12","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1183\/13993003.01204-2015","volume":"47","author":"F Bonella","year":"2016","unstructured":"Bonella F, Wijsenbeek M, Molina-Molina M, Duck A, Mele R, Geissler K, Wuyts W. European IPF patient charter: unmet needs and a call to action for healthcare policymakers. Eur Respir J. 2016;47(2):597\u2013606.","journal-title":"Eur Respir J"},{"issue":"3","key":"2997_CR13","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.hrtlng.2018.03.004","volume":"47","author":"RJ Shah","year":"2018","unstructured":"Shah RJ, Collard HR, Morisset J. Burden, resilience and coping in caregivers of patients with interstitial lung disease. Heart Lung. 2018;47(3):264\u20138.","journal-title":"Heart Lung"},{"key":"2997_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12890-015-0145-5","volume":"15","author":"C Sampson","year":"2015","unstructured":"Sampson C, Gill BH, Harrison NK, Nelson A, Byrne A. The care needs of patients with idiopathic pulmonary fibrosis and their carers (CaNoPy): results of a qualitative study. BMC Pulm Med. 2015;15:155.","journal-title":"BMC Pulm Med"},{"key":"2997_CR15","unstructured":"What is patient-centered care? N Engl J Med Catalyst. 2017;3(1)."},{"issue":"7","key":"2997_CR16","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1164\/rccm.201104-0668OC","volume":"184","author":"DJ Lamas","year":"2011","unstructured":"Lamas DJ, Kawut SM, Bagiella E, Philip N, Arcasoy SM, Lederer DJ. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. Am J Respir Crit Care Med. 2011;184(7):842\u20137.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"2997_CR17","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.jtcvs.2008.07.016","volume":"136","author":"A Watanabe","year":"2008","unstructured":"Watanabe A, Higami T, Ohori S, Koyanagi T, Nakashima S, Mawatari T. Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis? J Thorac Cardiovasc Surg. 2008;136(5):1357\u201363.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"3","key":"2997_CR18","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.chest.2022.03.042","volume":"162","author":"AM DeDent","year":"2022","unstructured":"DeDent AM, Collard HR, Thakur N. Disparities in rural populations with idiopathic pulmonary fibrosis. Chest. 2022;162(3):630\u20134.","journal-title":"Chest"},{"issue":"1","key":"2997_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12890-017-0560-x","volume":"18","author":"GP Cosgrove","year":"2018","unstructured":"Cosgrove GP, Bianchi P, Danese S, Lederer DJ. Barriers to timely diagnosis of interstitial lung disease in the real world: the INTENSITY survey. BMC Pulm Med. 2018;18(1):9.","journal-title":"BMC Pulm Med"},{"key":"2997_CR20","doi-asserted-by":"crossref","unstructured":"Cottin VA-O, Martinez FJ, Smith VA-O, Walsh SLF. Multidisciplinary teams in the clinical care of fibrotic interstitial lung disease: current perspectives. Eur Respir Rev. 2022;31(165):220003.","DOI":"10.1183\/16000617.0003-2022"},{"issue":"4","key":"2997_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1097\/MCP.0000000000000971","volume":"29","author":"G Nakshbandi","year":"2023","unstructured":"Nakshbandi G, Moor CC, Wijsenbeek MS. Role of the internet of medical things in care for patients with interstitial lung disease. Curr Opin Pulm Med. 2023;29(4):285\u201392.","journal-title":"Curr Opin Pulm Med"},{"key":"2997_CR22","unstructured":"Global strategy on digital health 2020-2025. World Health Organization (WHO); 2021. https:\/\/www.who.int\/publications\/i\/item\/9789240020924."},{"issue":"3","key":"2997_CR23","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1164\/rccm.202002-0328OC","volume":"202","author":"CC Moor","year":"2020","unstructured":"Moor CC, Mostard RLM, Grutters JC, Bresser P, Aerts J, Chavannes NH, Wijsenbeek MS. Home Monitoring in patients with idiopathic pulmonary fibrosis. A Randomized Controlled Trial. Am J Respir Crit Care Med. 2020;202(3):393\u2013401.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"2997_CR24","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1164\/rccm.201511-2152OC","volume":"194","author":"AM Russell","year":"2016","unstructured":"Russell AM, Adamali H, Molyneaux PL, Lukey PT, Marshall RP, Renzoni EA, et al. Daily Home Spirometry: An Effective Tool for detecting progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2016;194(8):989\u201397.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2997_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12890-023-02336-4","volume":"23","author":"G Nakshbandi","year":"2023","unstructured":"Nakshbandi G, Moor CC, Antoniou K, Cottin V, Hoffmann-Vold AM, Koemans EA, et al. Study protocol of an international patient-led registry in patients with pulmonary fibrosis using online home monitoring: I-FILE. BMC Pulm Med. 2023;23(1):51.","journal-title":"BMC Pulm Med"},{"issue":"1","key":"2997_CR26","doi-asserted-by":"publisher","first-page":"2102312","DOI":"10.1183\/13993003.02312-2021","volume":"59","author":"CM Nolan","year":"2022","unstructured":"Nolan CM, Birring SS. PROMising developments in IPF patient-reported outcome measures. Eur Respir J. 2022;59(1):2102312.","journal-title":"Eur Respir J"},{"issue":"4","key":"2997_CR27","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/MCP.0000000000000970","volume":"29","author":"CC Moor","year":"2023","unstructured":"Moor CC, Wijsenbeek MS. The lung way home: ready for home monitoring in lung diseases? Curr Opin Pulm Med. 2023;29(4):256\u20138.","journal-title":"Curr Opin Pulm Med"},{"issue":"1","key":"2997_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S2213-2600(22)00228-4","volume":"11","author":"MS Wijsenbeek","year":"2023","unstructured":"Wijsenbeek MS, Moor CC, Johannson KA, Jackson PD, Khor YH, Kondoh Y, et al. Home monitoring in interstitial lung diseases. Lancet Respir Med. 2023;11(1):97\u2013110.","journal-title":"Lancet Respir Med"},{"issue":"7","key":"2997_CR29","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1513\/AnnalsATS.201512-836OC","volume":"13","author":"J Morisset","year":"2016","unstructured":"Morisset J, Dub\u00e9 BP, Garvey C, Bourbeau J, Collard HR, Swigris JJ, Lee JS. The Unmet Educational needs of patients with interstitial lung disease. Setting the stage for tailored Pulmonary Rehabilitation. Ann Am Thorac Soc. 2016;13(7):1026\u201333.","journal-title":"Ann Am Thorac Soc"},{"key":"2997_CR30","doi-asserted-by":"crossref","first-page":"711194","DOI":"10.3389\/fmed.2021.711194","volume":"8","author":"IG van der Sar","year":"2021","unstructured":"van der Sar IG, Jones S, Clarke DL, Bonella F, Fourrier JM, Lewandowska K, et al. Patient reported experiences and delays during the diagnostic pathway for pulmonary fibrosis: a multinational European Survey. Front Med (Lausanne). 2021;8:711194.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"2997_CR31","doi-asserted-by":"publisher","first-page":"e000207","DOI":"10.1136\/bmjoq-2017-000207","volume":"7","author":"D Ramadurai","year":"2018","unstructured":"Ramadurai D, Corder S, Churney T, Graney B, Harshman A, Meadows S, Swigris JJ. Understanding the informational needs of patients with IPF and their caregivers: \u2018You get diagnosed, and you ask this question right away, what does this mean?\u2018. BMJ Open Qual. 2018;7(1):e000207.","journal-title":"BMJ Open Qual"},{"issue":"1","key":"2997_CR32","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12931-021-01676-1","volume":"22","author":"TM Alfaro","year":"2021","unstructured":"Alfaro TM, Wijsenbeek MS, Powell P, Stolz D, Hurst JR, Kreuter M, Moor CC. Educational aspects of rare and orphan lung diseases. Respir Res. 2021;22(1):92.","journal-title":"Respir Res"},{"issue":"1","key":"2997_CR33","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12931-021-01843-4","volume":"22","author":"JS Grewal","year":"2021","unstructured":"Grewal JS, Kawano-Dourado L, Ryerson CJ. The opportunities and challenges of social media in interstitial lung disease: a viewpoint. Respir Res. 2021;22(1):247.","journal-title":"Respir Res"},{"issue":"5","key":"2997_CR34","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1513\/AnnalsATS.201809-644OC","volume":"16","author":"GC Goobie","year":"2019","unstructured":"Goobie GC, Guler SA, Johannson KA, Fisher JH, Ryerson CJ. YouTube Videos as a source of misinformation on idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2019;16(5):572\u20139.","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"2997_CR35","doi-asserted-by":"publisher","first-page":"576","DOI":"10.34197\/ats-scholar.2022-0054OC","volume":"3","author":"S Ong","year":"2022","unstructured":"Ong S, Koo J, Johannson KA, Ryerson CJ, Goobie GC. Content analysis of idiopathic pulmonary fibrosis-related information on Twitter. ATS Sch. 2022;3(4):576\u201387.","journal-title":"ATS Sch"},{"issue":"2","key":"2997_CR36","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ccm.2021.03.013","volume":"42","author":"JH Fisher","year":"2021","unstructured":"Fisher JH, Cottin V. Care Delivery models and interstitial lung disease: the role of the Specialized Center. Clin Chest Med. 2021;42(2):347\u201355.","journal-title":"Clin Chest Med"},{"issue":"1","key":"2997_CR37","first-page":"848","volume":"17","author":"M Silva","year":"2022","unstructured":"Silva M, Fernandes A, Pereira AR, Madanelo S, Clem\u00eancio T, Ferreira PG. Awareness towards the main ILD among primary care physicians. Multidiscip Respir Med. 2022;17(1):848.","journal-title":"Multidiscip Respir Med"},{"key":"2997_CR38","doi-asserted-by":"crossref","unstructured":"Brereton CJ, Wallis T, Casey M, Fox L, Pontopiddan K, Laws D et al. Time taken from primary care referral to a specialist centre diagnosis of idiopathic pulmonary fibrosis: an opportunity to improve patient outcomes? ERJ Open Res. 2020;6(2).","DOI":"10.1183\/23120541.00120-2020"},{"issue":"1","key":"2997_CR39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12931-019-1076-0","volume":"20","author":"N Hoyer","year":"2019","unstructured":"Hoyer N, Prior TS, Bendstrup E, Wilcke T, Shaker SB. Risk factors for diagnostic delay in idiopathic pulmonary fibrosis. Respir Res. 2019;20(1):103.","journal-title":"Respir Res"},{"issue":"1","key":"2997_CR40","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12931-019-1228-2","volume":"20","author":"D Pritchard","year":"2019","unstructured":"Pritchard D, Adegunsoye A, Lafond E, Pugashetti JV, DiGeronimo R, Boctor N, et al. Diagnostic test interpretation and referral delay in patients with interstitial lung disease. Respir Res. 2019;20(1):253.","journal-title":"Respir Res"},{"key":"2997_CR41","doi-asserted-by":"crossref","unstructured":"Hoyer N, Prior TS, Bendstrup E, Shaker SB. Diagnostic delay in IPF impacts progression-free survival, quality of life and hospitalisation rates. BMJ Open Respir Res. 2022;9(1).","DOI":"10.1136\/bmjresp-2022-001276"},{"key":"2997_CR42","unstructured":"PF awareness month. EU-PPF. https:\/\/www.eu-pff.org\/awareness-campaigns\/."},{"key":"2997_CR43","doi-asserted-by":"crossref","unstructured":"Farrand E, Swigris JJ. Digital outcome measures in pulmonary clinical trials. Curr Opin Pulm Med. 2023;29(4).","DOI":"10.1097\/MCP.0000000000000972"},{"issue":"3","key":"2997_CR44","doi-asserted-by":"publisher","first-page":"2103187","DOI":"10.1183\/13993003.03187-2021","volume":"61","author":"SK Rajan","year":"2023","unstructured":"Rajan SK, Cottin V, Dhar R, Danoff S, Flaherty KR, Brown KK, et al. Progressive pulmonary fibrosis: an expert group consensus statement. Eur Respir J. 2023;61(3):2103187.","journal-title":"Eur Respir J"},{"issue":"12","key":"2997_CR45","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S2213-2600(17)30383-1","volume":"5","author":"M Kreuter","year":"2017","unstructured":"Kreuter M, Bendstrup E, Russell AM, Bajwah S, Lindell K, Adir Y, et al. Palliative care in interstitial lung disease: living well. Lancet Respir Med. 2017;5(12):968\u201380.","journal-title":"Lancet Respir Med"},{"key":"2997_CR46","doi-asserted-by":"crossref","unstructured":"Cassidy N, Fox L, Love M, Byrne I, Doyle AM, Korn B et al. Fibrotic interstitial lung disease - palliative care needs: a World-Caf\u00e9 qualitative study. BMJ Support Palliat Care. 2021.","DOI":"10.1136\/bmjspcare-2021-003249"},{"issue":"2","key":"2997_CR47","doi-asserted-by":"publisher","first-page":"e0297832","DOI":"10.1371\/journal.pone.0297832","volume":"19","author":"C Bramhill","year":"2024","unstructured":"Bramhill C, Langan D, Mulryan H, Eustace-Cook J, Russell AM, Brady AM. A scoping review of the unmet needs of patients diagnosed with idiopathic pulmonary fibrosis (IPF). PLoS ONE. 2024;19(2):e0297832.","journal-title":"PLoS ONE"},{"issue":"1","key":"2997_CR48","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/resp.14154","volume":"27","author":"L Lancaster","year":"2022","unstructured":"Lancaster L, Bonella F, Inoue Y, Cottin V, Siddall J, Small M, Langley J. Idiopathic pulmonary fibrosis: physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden. Respirology. 2022;27(1):66\u201375.","journal-title":"Respirology"},{"key":"2997_CR49","doi-asserted-by":"crossref","unstructured":"Moor CC, Wijsenbeek MS, Balestro E, Biondini D, Bondue B, Cottin V et al. Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey. ERJ Open Res. 2019;5(4).","DOI":"10.1183\/23120541.00124-2019"},{"key":"2997_CR50","doi-asserted-by":"publisher","first-page":"107659","DOI":"10.1016\/j.rmed.2024.107659","volume":"227","author":"M Wells","year":"2024","unstructured":"Wells M, Harding S, Dixon G, Buckley K, Russell A-M, Barratt SL. Patient and caregiver shared experiences of pulmonary fibrosis (PF): a systematic literature review. Respir Med. 2024;227:107659.","journal-title":"Respir Med"},{"issue":"160","key":"2997_CR51","doi-asserted-by":"publisher","first-page":"210026","DOI":"10.1183\/16000617.0026-2021","volume":"30","author":"M Kalluri","year":"2021","unstructured":"Kalluri M, Luppi F, Vancheri A, Vancheri C, Balestro E, Varone F, et al. Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here? Eur Respiratory Rev. 2021;30(160):210026.","journal-title":"Eur Respiratory Rev"},{"issue":"5","key":"2997_CR52","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/MCP.0000000000001095","volume":"30","author":"KI Aronson","year":"2024","unstructured":"Aronson KI, Swigris JJ, Wijsenbeek M. Integrating the assessment of quality of life in care and research in pulmonary fibrosis. Curr Opin Pulm Med. 2024;30(5):508\u201315.","journal-title":"Curr Opin Pulm Med"},{"issue":"suppl 63","key":"2997_CR53","first-page":"PA1320","volume":"54","author":"A-M Russell","year":"2019","unstructured":"Russell A-M, Datta A, Newell K, Jones S, Conway J, Saktkoo LA, Wickremasinghe M. Development of a patient reported experience measure (PREM) for idiopathic pulmonary fibrosis (IPF). Eur Respir J. 2019;54(suppl 63):PA1320.","journal-title":"Eur Respir J"},{"issue":"2","key":"2997_CR54","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12325-015-0183-7","volume":"32","author":"A Duck","year":"2015","unstructured":"Duck A, Pigram L, Errhalt P, Ahmed D, Chaudhuri N. IPF Care: a support program for patients with idiopathic pulmonary fibrosis treated with pirfenidone in Europe. Adv Ther. 2015;32(2):87\u2013107.","journal-title":"Adv Ther"},{"key":"2997_CR55","doi-asserted-by":"crossref","unstructured":"van Manen MJ, Kreuter M, van den Blink B, Oltmanns U, Palmowski K, Brunnemer E et al. What patients with pulmonary fibrosis and their partners think: a live, educative survey in the Netherlands and Germany. ERJ Open Res. 2017;3(1).","DOI":"10.1183\/23120541.00065-2016"},{"key":"2997_CR56","doi-asserted-by":"crossref","unstructured":"Janssen DJA, Bajwah S, Boon MH, Coleman C, Currow DC, Devillers A et al. European Respiratory Society clinical practice guideline: palliative care for people with COPD or interstitial lung disease. Eur Respir J. 2023;62(2).","DOI":"10.1183\/13993003.02014-2022"},{"issue":"1","key":"2997_CR57","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12904-023-01185-6","volume":"22","author":"J Koffman","year":"2023","unstructured":"Koffman J, Shapiro GK, Schulz-Quach C. Enhancing equity and diversity in palliative care clinical practice, research and education. BMC Palliat Care. 2023;22(1):64.","journal-title":"BMC Palliat Care"},{"key":"2997_CR58","doi-asserted-by":"crossref","unstructured":"Wijsenbeek MS, Bonella F, Orsatti L, Russell AM, Valenzuela C, Wuyts WA, Baile WF. Communicating with patients with idiopathic pulmonary fibrosis: can we do it better? ERJ Open Res. 2022;8(1).","DOI":"10.1183\/23120541.00422-2021"},{"key":"2997_CR59","doi-asserted-by":"crossref","unstructured":"Masefield S, Cassidy N, Ross D, Powell P, Wells A. Communication difficulties reported by patients diagnosed with idiopathic pulmonary fibrosis and their carers: a European focus group study. ERJ Open Res. 2019;5(2).","DOI":"10.1183\/23120541.00055-2019"},{"key":"2997_CR60","doi-asserted-by":"crossref","unstructured":"Huapaya JA, Wilfong EM, Harden CT, Brower RG, Danoff SK. Risk factors for mortality and mortality rates in interstitial lung disease patients in the intensive care unit. Eur Respir Rev. 2018;27(150).","DOI":"10.1183\/16000617.0061-2018"},{"key":"2997_CR61","unstructured":"Kroger ABL, Long S, Sanchez P. General Best Practice guidelines for immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP)."},{"issue":"2","key":"2997_CR62","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1136\/thorax-2023-220012","volume":"79","author":"J Zhu","year":"2024","unstructured":"Zhu J, Zhou D, Yu M, Li Y. Appraising the causal role of smoking in idiopathic pulmonary fibrosis: a mendelian randomization study. Thorax. 2024;79(2):179.","journal-title":"Thorax"},{"issue":"2","key":"2997_CR63","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1183\/09031936.00189309","volume":"35","author":"B Balbi","year":"2010","unstructured":"Balbi B, Cottin V, Singh S, De Wever W, Herth FJF, Robalo Cordeiro C. Smoking-related lung diseases: a clinical perspective. Eur Respir J. 2010;35(2):231.","journal-title":"Eur Respir J"},{"key":"2997_CR64","doi-asserted-by":"crossref","unstructured":"Kokosi MA, Margaritopoulos GA, Wells AU. Personalised medicine in interstitial lung diseases: number 6 in the Series Personalised medicine in respiratory diseases edited by Renaud Louis and Nicolas Roche. Eur Respir Rev. 2018;27(148).","DOI":"10.1183\/16000617.0117-2017"},{"issue":"1","key":"2997_CR65","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1164\/rccm.202201-0124OC","volume":"207","author":"JV Pugashetti","year":"2023","unstructured":"Pugashetti JV, Adegunsoye A, Wu Z, Lee CT, Srikrishnan A, Ghodrati S, et al. Validation of proposed Criteria for Progressive Pulmonary Fibrosis. Am J Respir Crit Care Med. 2023;207(1):69\u201376.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2997_CR66","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1164\/rccm.202208-1639ED","volume":"207","author":"V Cottin","year":"2023","unstructured":"Cottin V. Criteria for Progressive Pulmonary Fibrosis: getting the Horse Ready for the Cart. Am J Respir Crit Care Med. 2023;207(1):11\u20133.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"2997_CR67","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","volume":"8","author":"PM George","year":"2020","unstructured":"George PM, Spagnolo P, Kreuter M, Altinisik G, Bonifazi M, Martinez FJ, et al. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir Med. 2020;8(9):925\u201334.","journal-title":"Lancet Respir Med"},{"issue":"18","key":"2997_CR68","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in Progressive Fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718\u201327.","journal-title":"N Engl J Med"},{"issue":"5","key":"2997_CR69","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","volume":"8","author":"AU Wells","year":"2020","unstructured":"Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020;8(5):453\u201360.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"2997_CR70","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1164\/rccm.201902-0456OC","volume":"200","author":"TM Dempsey","year":"2019","unstructured":"Dempsey TM, Sangaralingham LR, Yao X, Sanghavi D, Shah ND, Limper AH. Clinical effectiveness of Antifibrotic Medications for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2019;200(2):168\u201374.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"2997_CR71","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.chest.2021.06.049","volume":"160","author":"T Petnak","year":"2021","unstructured":"Petnak T, Lertjitbanjong P, Thongprayoon C, Moua T. Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: a systematic review and Meta-analysis. Chest. 2021;160(5):1751\u201363.","journal-title":"Chest"},{"key":"2997_CR72","doi-asserted-by":"crossref","unstructured":"Wijsenbeek M, Swigris JJ, Inoue Y, Kreuter M, Maher TM, Suda T et al. Effects of Nintedanib on symptoms in patients with progressive pulmonary fibrosis. Eur Respir J. 2024;63(2).","DOI":"10.1183\/13993003.00752-2023"},{"key":"2997_CR73","doi-asserted-by":"crossref","unstructured":"van Manen MJG, Birring SS, Vancheri C, Vindigni V, Renzoni E, Russell AM et al. Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2017;50(4).","DOI":"10.1183\/13993003.01157-2017"},{"issue":"1","key":"2997_CR74","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12931-020-01458-1","volume":"21","author":"CC Moor","year":"2020","unstructured":"Moor CC, Mostard RLM, Grutters JC, Bresser P, Aerts JGJV, Dirksen CD, et al. Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study. Respir Res. 2020;21(1):196.","journal-title":"Respir Res"},{"key":"2997_CR75","unstructured":"MacIsaac S, Somboonviboon D, Scallan C, Kolb M. Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials. Expert Opin Emerg Drugs.1\u201310."},{"key":"2997_CR76","doi-asserted-by":"publisher","first-page":"116282","DOI":"10.1016\/j.biopha.2024.116282","volume":"173","author":"J Ma","year":"2024","unstructured":"Ma J, Li G, Wang H, Mo C. Comprehensive review of potential drugs with anti-pulmonary fibrosis properties. Biomed Pharmacother. 2024;173:116282.","journal-title":"Biomed Pharmacother"},{"issue":"10038","key":"2997_CR77","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","volume":"387","author":"D Khanna","year":"2016","unstructured":"Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387(10038):2630\u201340.","journal-title":"Lancet"},{"issue":"10","key":"2997_CR78","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","volume":"8","author":"D Khanna","year":"2020","unstructured":"Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020;8(10):963\u201374.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"2997_CR79","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1164\/rccm.202306-1113ST","volume":"209","author":"G Raghu","year":"2024","unstructured":"Raghu G, Montesi SB, Silver RM, Hossain T, Macrea M, Herman D, et al. Treatment of systemic sclerosis-associated interstitial lung disease: evidence-based recommendations. An official American thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2024;209(2):137\u201352.","journal-title":"Am J Respir Crit Care Med"},{"issue":"21","key":"2997_CR80","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","volume":"366","author":"G Raghu","year":"2012","unstructured":"Raghu G, Anstrom KJ, King TE Jr., Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968\u201377.","journal-title":"N Engl J Med"},{"issue":"5","key":"2997_CR81","doi-asserted-by":"publisher","first-page":"2300441","DOI":"10.1183\/13993003.00441-2023","volume":"62","author":"D Zhang","year":"2023","unstructured":"Zhang D, Adegunsoye A, Oldham JM, Kozlitina J, Garcia N, Poonawalla M, et al. Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease. Eur Respir J. 2023;62(5):2300441.","journal-title":"Eur Respir J"},{"key":"2997_CR82","doi-asserted-by":"publisher","first-page":"871861","DOI":"10.3389\/fmed.2022.871861","volume":"9","author":"J Wang","year":"2022","unstructured":"Wang J, Wang X, Qi X, Sun Z, Zhang T, Cui Y, Shu Q. The efficacy and safety of Pirfenidone Combined with immunosuppressant therapy in connective tissue Disease-Associated interstitial lung disease: a 24-Week prospective controlled cohort study. Front Med (Lausanne). 2022;9:871861.","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"2997_CR83","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.3899\/jrheum.151322","volume":"43","author":"K Dinesh","year":"2016","unstructured":"Dinesh K, Carlo A, Aryeh F, Nader K, Ganesh R, Lorinda C, et al. An Open-label, phase II study of the Safety and Tolerability of Pirfenidone in patients with Scleroderma-associated interstitial lung disease: the LOTUSS Trial. J Rhuematol. 2016;43(9):1672.","journal-title":"J Rhuematol"},{"key":"2997_CR84","first-page":"1045","volume":"74","author":"D Khanna","year":"2022","unstructured":"Khanna D, Spino C, Bernstein E, Goldin J, Tashkin D, Roth M, Invest OBSI. Combination therapy of Mycophenolate Mofetil and Pirfenidone vs. mycophenolate alone: results from the Scleroderma Lung Study III. Arthritis Rheumatol. 2022;74:1045\u20137.","journal-title":"Arthritis Rheumatol"},{"key":"2997_CR85","doi-asserted-by":"crossref","unstructured":"Kapnadak SG, Raghu G. Lung transplantation for interstitial lung disease. Eur Respir Rev. 2021;30(161).","DOI":"10.1183\/16000617.0017-2021"},{"issue":"11","key":"2997_CR86","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.healun.2021.07.005","volume":"40","author":"LE Leard","year":"2021","unstructured":"Leard LE, Holm AM, Valapour M, Glanville AR, Attawar S, Aversa M, et al. Consensus document for the selection of lung transplant candidates: an update from the International Society for Heart and Lung Transplantation. J Heart Lung Transpl. 2021;40(11):1349\u201379.","journal-title":"J Heart Lung Transpl"},{"issue":"2","key":"2997_CR87","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S2213-2600(23)00002-4","volume":"11","author":"F Amati","year":"2023","unstructured":"Amati F, Spagnolo P, Oldham JM, Ryerson CJ, Stainer A, Gramegna A, et al. Treatable traits in interstitial lung diseases: a call to action. Lancet Respir Med. 2023;11(2):125\u20138.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"2997_CR88","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12890-018-0651-3","volume":"18","author":"S Carvajalino","year":"2018","unstructured":"Carvajalino S, Reigada C, Johnson MJ, Dzingina M, Bajwah S. Symptom prevalence of patients with fibrotic interstitial lung disease: a systematic literature review. BMC Pulm Med. 2018;18(1):78.","journal-title":"BMC Pulm Med"},{"issue":"2","key":"2997_CR89","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.rmed.2009.09.006","volume":"104","author":"JJ Swigris","year":"2010","unstructured":"Swigris JJ, Brown KK, Behr J, du Bois RM, King TE, Raghu G, Wamboldt FS. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med. 2010;104(2):296\u2013304.","journal-title":"Respir Med"},{"issue":"8","key":"2997_CR90","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1111\/resp.12360","volume":"19","author":"AE Holland","year":"2014","unstructured":"Holland AE, Fiore JF Jr., Bell EC, Goh N, Westall G, Symons K, et al. Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease. Respirology. 2014;19(8):1215\u201321.","journal-title":"Respirology"},{"key":"2997_CR91","doi-asserted-by":"crossref","unstructured":"Rajala K, Lehto JT, Sutinen E, Kautiainen H, Myll\u00e4rniemi M, Saarto T. mMRC dyspnoea scale indicates impaired quality of life and increased pain in patients with idiopathic pulmonary fibrosis. ERJ Open Res. 2017;3(4).","DOI":"10.1183\/23120541.00084-2017"},{"issue":"10","key":"2997_CR92","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1089\/jpm.2022.0548","volume":"26","author":"T Rautajoki","year":"2023","unstructured":"Rautajoki T, Lehto JT, Sutinen E, Bergman P, Sintonen H, Rajala K, et al. Dyspnea Associates with a widely impaired quality of life in idiopathic pulmonary fibrosis patients: a longitudinal study using 15D. J Palliat Med. 2023;26(10):1357\u201364.","journal-title":"J Palliat Med"},{"issue":"5","key":"2997_CR93","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1164\/rccm.200211-1311OC","volume":"168","author":"HR Collard","year":"2003","unstructured":"Collard HR, King TE Jr., Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168(5):538\u201342.","journal-title":"Am J Respir Crit Care Med"},{"key":"2997_CR94","doi-asserted-by":"crossref","unstructured":"Duke JD, Roy M, Daley S, Hoult J, Benzo R, Moua T. Association of patient-reported outcome measures with lung function and mortality in fibrotic interstitial lung disease: a prospective cohort study. ERJ Open Res. 2024;10(2).","DOI":"10.1183\/23120541.00591-2023"},{"key":"2997_CR95","doi-asserted-by":"crossref","unstructured":"Holland AE, Spathis A, Marsaa K, Bausewein C, Ahmadi Z, Burge AT et al. European Respiratory Society Clinical Practice Guideline on symptom management for adults with serious respiratory illness. Eur Respir J. 2024:2400335.","DOI":"10.1183\/13993003.00335-2024"},{"issue":"10","key":"2997_CR96","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1164\/rccm.202009-3608ST","volume":"202","author":"SS Jacobs","year":"2020","unstructured":"Jacobs SS, Krishnan JA, Lederer DJ, Ghazipura M, Hossain T, Tan AM, et al. Home Oxygen Therapy for adults with chronic lung disease. An official American thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;202(10):e121\u201341.","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 1","key":"2997_CR97","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1136\/thoraxjnl-2015-206865","volume":"70","author":"M Hardinge","year":"2015","unstructured":"Hardinge M, Annandale J, Bourne S, Cooper B, Evans A, Freeman D, et al. British thoracic society guidelines for home oxygen use in adults. Thorax. 2015;70(Suppl 1):i1\u201343.","journal-title":"Thorax"},{"key":"2997_CR98","doi-asserted-by":"crossref","unstructured":"Khor YH, Harrison A, Robinson J, Goh NSL, Glaspole I, McDonald CF. Moderate resting hypoxaemia in fibrotic interstitial lung disease. Eur Respir J. 2021;57(1).","DOI":"10.1183\/13993003.01563-2020"},{"key":"2997_CR99","doi-asserted-by":"publisher","first-page":"106659","DOI":"10.1016\/j.rmed.2021.106659","volume":"189","author":"A Palm","year":"2021","unstructured":"Palm A, Ekstr\u00f6m M. Hypoxemia severity and survival in ILD and COPD on long-term oxygen therapy - the population-based DISCOVERY study. Respir Med. 2021;189:106659.","journal-title":"Respir Med"},{"key":"2997_CR100","doi-asserted-by":"crossref","unstructured":"Tikellis G, Hoffman M, Mellerick C, Burge AT, Holland AE. Barriers to and facilitators of the use of oxygen therapy in people living with an interstitial lung disease: a systematic review of qualitative evidence. Eur Respir Rev. 2023;32(169).","DOI":"10.1183\/16000617.0066-2023"},{"issue":"11","key":"2997_CR101","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1513\/AnnalsATS.202304-391CME","volume":"20","author":"KP Clark","year":"2023","unstructured":"Clark KP, Degenholtz HB, Lindell KO, Kass DJ. Supplemental Oxygen Therapy in interstitial lung disease: a narrative review. Ann Am Thorac Soc. 2023;20(11):1541\u20139.","journal-title":"Ann Am Thorac Soc"},{"issue":"10","key":"2997_CR102","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S2213-2600(18)30289-3","volume":"6","author":"D Visca","year":"2018","unstructured":"Visca D, Mori L, Tsipouri V, Fleming S, Firouzi A, Bonini M, et al. Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial. Lancet Respir Med. 2018;6(10):759\u201370.","journal-title":"Lancet Respir Med"},{"issue":"7","key":"2997_CR103","first-page":"CD011716","volume":"7","author":"C Sharp","year":"2016","unstructured":"Sharp C, Adamali H, Millar AB. Ambulatory and short-burst oxygen for interstitial lung disease. Cochrane Database Syst Rev. 2016;7(7):CD011716.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"2997_CR104","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1513\/AnnalsATS.201611-934OC","volume":"14","author":"YH Khor","year":"2017","unstructured":"Khor YH, Goh NSL, McDonald CF, Holland AE. Oxygen therapy for interstitial lung disease. A mismatch between patient expectations and experiences. Ann Am Thorac Soc. 2017;14(6):888\u201395.","journal-title":"Ann Am Thorac Soc"},{"issue":"5","key":"2997_CR105","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.hrtlng.2017.07.001","volume":"46","author":"BA Graney","year":"2017","unstructured":"Graney BA, Wamboldt FS, Baird S, Churney T, Fier K, Korn M, et al. Looking ahead and behind at supplemental oxygen: a qualitative study of patients with pulmonary fibrosis. Heart Lung. 2017;46(5):387\u201393.","journal-title":"Heart Lung"},{"key":"2997_CR106","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.rmed.2018.03.025","volume":"138","author":"D Ramadurai","year":"2018","unstructured":"Ramadurai D, Riordan M, Graney B, Churney T, Olson AL, Swigris JJ. The impact of carrying supplemental oxygen on exercise capacity and dyspnea in patients with interstitial lung disease. Respir Med. 2018;138:32\u20137.","journal-title":"Respir Med"},{"issue":"1","key":"2997_CR107","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1513\/AnnalsATS.201703-209OC","volume":"15","author":"SS Jacobs","year":"2018","unstructured":"Jacobs SS, Lindell KO, Collins EG, Garvey CM, Hernandez C, McLaughlin S, et al. Patient perceptions of the Adequacy of Supplemental Oxygen Therapy. Results of the American Thoracic Society Nursing Assembly Oxygen Working Group Survey. Ann Am Thorac Soc. 2018;15(1):24\u201332.","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"2997_CR108","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12931-018-0884-y","volume":"19","author":"S Perez-Bogerd","year":"2018","unstructured":"Perez-Bogerd S, Wuyts W, Barbier V, Demeyer H, Van Muylem A, Janssens W, Troosters T. Short and long-term effects of pulmonary rehabilitation in interstitial lung diseases: a randomised controlled trial. Respir Res. 2018;19(1):182.","journal-title":"Respir Res"},{"issue":"8","key":"2997_CR109","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1136\/thorax-2022-219792","volume":"78","author":"K Kataoka","year":"2023","unstructured":"Kataoka K, Nishiyama O, Ogura T, Mori Y, Kozu R, Arizono S, et al. Long-term effect of pulmonary rehabilitation in idiopathic pulmonary fibrosis: a randomised controlled trial. Thorax. 2023;78(8):784\u201391.","journal-title":"Thorax"},{"issue":"1","key":"2997_CR110","doi-asserted-by":"publisher","first-page":"6874","DOI":"10.1038\/s41598-021-86326-8","volume":"11","author":"YH Khor","year":"2021","unstructured":"Khor YH, Saravanan K, Holland AE, Lee JYT, Ryerson CJ, McDonald CF, Goh NSL. A mixed-methods pilot study of handheld fan for breathlessness in interstitial lung disease. Sci Rep. 2021;11(1):6874.","journal-title":"Sci Rep"},{"issue":"suppl 66","key":"2997_CR111","first-page":"164","volume":"60","author":"H Morris","year":"2022","unstructured":"Morris H, Zakis K, Swale J, Hayton C. Effectiveness of fan therapy in breathlessness management in Fibrotic interstitial lung disease. Eur Respir J. 2022;60(suppl 66):164.","journal-title":"Eur Respir J"},{"issue":"3","key":"2997_CR112","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jpainsymman.2019.04.011","volume":"58","author":"Y Qian","year":"2019","unstructured":"Qian Y, Wu Y, Rozman de Moraes A, Yi X, Geng Y, Dibaj S, et al. Fan therapy for the treatment of Dyspnea in adults: a systematic review. J Pain Symptom Manage. 2019;58(3):481\u20136.","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"2997_CR113","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/SPC.0000000000000674","volume":"17","author":"M Ekstr\u00f6m","year":"2023","unstructured":"Ekstr\u00f6m M, Janssen DJA. Should opioids be used for breathlessness and in whom? A PRO and CON debate of the evidence. Curr Opin Support Palliat Care. 2023;17(4):263\u20139.","journal-title":"Curr Opin Support Palliat Care"},{"issue":"1","key":"2997_CR114","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12931-020-01452-7","volume":"21","author":"S Kronborg-White","year":"2020","unstructured":"Kronborg-White S, Andersen CU, Kohberg C, Hilberg O, Bendstrup E. Palliation of chronic breathlessness with morphine in patients with fibrotic interstitial lung disease - a randomised placebo-controlled trial. Respir Res. 2020;21(1):195.","journal-title":"Respir Res"},{"issue":"3","key":"2997_CR115","doi-asserted-by":"publisher","first-page":"2300702","DOI":"10.1183\/13993003.00702-2023","volume":"62","author":"DH Ferreira","year":"2023","unstructured":"Ferreira DH, Ekstr\u00f6m M, Bajwah S, Fazekas B, Currow DC. Regular, low-dose, sustained-release morphine for persisting breathlessness in interstitial lung disease: a randomised, double-blind, placebo-controlled, crossover trial. Eur Respir J. 2023;62(3):2300702.","journal-title":"Eur Respir J"},{"key":"2997_CR116","doi-asserted-by":"crossref","unstructured":"Bajwah S, Davies JM, Tanash H, Currow DC, Oluyase AO, Ekstr\u00f6m M. Safety of benzodiazepines and opioids in interstitial lung disease: a national prospective study. Eur Respir J. 2018;52(6).","DOI":"10.1183\/13993003.01278-2018"},{"issue":"9","key":"2997_CR117","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1513\/AnnalsATS.202302-174OC","volume":"20","author":"P Saunders","year":"2023","unstructured":"Saunders P, Wu Z, Fahy WA, Stewart ID, Saini G, Smith DJF, et al. The Burden and Impact of Cough in patients with idiopathic pulmonary fibrosis: an analysis of the prospective observational PROFILE study. Ann Am Thorac Soc. 2023;20(9):1267\u201373.","journal-title":"Ann Am Thorac Soc"},{"issue":"141","key":"2997_CR118","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1183\/16000617.0090-2015","volume":"25","author":"MJ van Manen","year":"2016","unstructured":"van Manen MJ, Birring SS, Vancheri C, Cottin V, Renzoni EA, Russell AM, Wijsenbeek MS. Cough in idiopathic pulmonary fibrosis. Eur Respir Rev. 2016;25(141):278\u201386.","journal-title":"Eur Respir Rev"},{"key":"2997_CR119","doi-asserted-by":"crossref","unstructured":"Khor YH, Johannson KA, Marcoux V, Fisher JH, Assayag D, Manganas H et al. Epidemiology and prognostic significance of Cough in Fibrotic interstitial lung disease. Am J Respir Crit Care Med. 2024.","DOI":"10.1164\/rccm.202311-2101OC"},{"issue":"1","key":"2997_CR120","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11739-018-1960-5","volume":"14","author":"E Bargagli","year":"2019","unstructured":"Bargagli E, Di Masi M, Perruzza M, Vietri L, Bergantini L, Torricelli E, et al. The pathogenetic mechanisms of cough in idiopathic pulmonary fibrosis. Intern Emerg Med. 2019;14(1):39\u201343.","journal-title":"Intern Emerg Med"},{"issue":"2","key":"2997_CR121","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00011-004-1321-x","volume":"54","author":"SS Birring","year":"2005","unstructured":"Birring SS, Parker D, McKenna S, Hargadon B, Brightling CE, Pavord ID, Bradding P. Sputum Eosinophilia in idiopathic pulmonary fibrosis. Inflamm Res. 2005;54(2):51\u20136.","journal-title":"Inflamm Res"},{"key":"2997_CR122","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1745-9974-7-2","volume":"7","author":"RM Jones","year":"2011","unstructured":"Jones RM, Hilldrup S, Hope-Gill BD, Eccles R, Harrison NK. Mechanical induction of cough in idiopathic pulmonary fibrosis. Cough. 2011;7:2.","journal-title":"Cough"},{"issue":"12","key":"2997_CR123","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/thx.2006.064337","volume":"61","author":"AE Vertigan","year":"2006","unstructured":"Vertigan AE, Theodoros DG, Gibson PG, Winkworth AL. Efficacy of speech pathology management for chronic cough: a randomised placebo controlled trial of treatment efficacy. Thorax. 2006;61(12):1065\u20139.","journal-title":"Thorax"},{"issue":"2","key":"2997_CR124","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1136\/thoraxjnl-2016-208843","volume":"72","author":"SA Chamberlain Mitchell","year":"2017","unstructured":"Chamberlain Mitchell SA, Garrod R, Clark L, Douiri A, Parker SM, Ellis J, et al. Physiotherapy, and speech and language therapy intervention for patients with refractory chronic cough: a multicentre randomised control trial. Thorax. 2017;72(2):129\u201336.","journal-title":"Thorax"},{"key":"2997_CR125","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1745-9974-6-5","volume":"6","author":"NM Ryan","year":"2010","unstructured":"Ryan NM, Vertigan AE, Bone S, Gibson PG. Cough reflex sensitivity improves with speech language pathology management of refractory chronic cough. Cough. 2010;6:5.","journal-title":"Cough"},{"issue":"4","key":"2997_CR126","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.chest.2018.06.038","volume":"154","author":"SS Birring","year":"2018","unstructured":"Birring SS, Kavanagh JE, Irwin RS, Keogh KA, Lim KG, Ryu JH. Collaborators. Treatment of interstitial lung Disease Associated Cough: CHEST Guideline and Expert Panel Report. Chest. 2018;154(4):904\u201317.","journal-title":"Chest"},{"issue":"8","key":"2997_CR127","doi-asserted-by":"publisher","first-page":"EVIDoa2300083","DOI":"10.1056\/EVIDoa2300083","volume":"2","author":"TM Maher","year":"2023","unstructured":"Maher TM, Avram C, Bortey E, Hart SP, Hirani N, Molyneux PL, et al. Nalbuphine tablets for Cough in patients with idiopathic pulmonary fibrosis. NEJM Evid. 2023;2(8):EVIDoa2300083.","journal-title":"NEJM Evid"},{"issue":"4","key":"2997_CR128","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S2213-2600(23)00432-0","volume":"12","author":"Z Wu","year":"2024","unstructured":"Wu Z, Spencer LG, Banya W, Westoby J, Tudor VA, Rivera-Ortega P, et al. Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial. Lancet Respir Med. 2024;12(4):273\u201380.","journal-title":"Lancet Respir Med"},{"key":"2997_CR129","doi-asserted-by":"crossref","unstructured":"Morice AH, Millqvist E, Bieksiene K, Birring SS, Dicpinigaitis P, Domingo Ribas C et al. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J. 2020;55(1).","DOI":"10.1183\/13993003.01136-2019"},{"issue":"6","key":"2997_CR130","doi-asserted-by":"publisher","first-page":"398","DOI":"10.7326\/0003-4819-157-6-201209180-00003","volume":"157","author":"MR Horton","year":"2012","unstructured":"Horton MR, Santopietro V, Mathew L, Horton KM, Polito AJ, Liu MC, et al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med. 2012;157(6):398\u2013406.","journal-title":"Ann Intern Med"},{"issue":"2","key":"2997_CR131","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s41030-021-00162-9","volume":"7","author":"FJ Martinez","year":"2021","unstructured":"Martinez FJ, Afzal AS, Smith JA, Ford AP, Li JJ, Li Y, et al. Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial. Pulm Ther. 2021;7(2):471\u201386.","journal-title":"Pulm Ther"},{"issue":"5","key":"2997_CR132","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1016\/j.chest.2020.04.047","volume":"158","author":"V Kahlmann","year":"2020","unstructured":"Kahlmann V, Moor CC, Wijsenbeek MS. Managing fatigue in patients with interstitial lung disease. Chest. 2020;158(5):2026\u201333.","journal-title":"Chest"},{"issue":"1","key":"2997_CR133","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-019-0096-x","volume":"5","author":"J Grunewald","year":"2019","unstructured":"Grunewald J, Grutters JC, Arkema EV, Saketkoo LA, Moller DR, M\u00fcller-Quernheim J. Sarcoidosis Nat Reviews Disease Primers. 2019;5(1):45.","journal-title":"Sarcoidosis Nat Reviews Disease Primers"},{"issue":"3","key":"2997_CR134","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1183\/09031936.00117710","volume":"38","author":"RGJ Marcellis","year":"2011","unstructured":"Marcellis RGJ, Lenssen AF, Elfferich MDP, De Vries J, Kassim S, Foerster K, Drent M. Exercise capacity, muscle strength and fatigue in sarcoidosis. Eur Respir J. 2011;38(3):628.","journal-title":"Eur Respir J"},{"key":"2997_CR135","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.rmed.2016.05.010","volume":"116","author":"B Strookappe","year":"2016","unstructured":"Strookappe B, De Vries J, Elfferich M, Kuijpers P, Knevel T, Drent M. Predictors of fatigue in sarcoidosis: the value of exercise testing. Respir Med. 2016;116:49\u201354.","journal-title":"Respir Med"},{"key":"2997_CR136","doi-asserted-by":"crossref","unstructured":"Baughman RP, Valeyre D, Korsten P, Mathioudakis AG, Wuyts WA, Wells A et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. 2021;58(6).","DOI":"10.1183\/13993003.04079-2020"},{"key":"2997_CR137","doi-asserted-by":"crossref","unstructured":"Bloem AEM, Mostard RLM, Stoot N, Vercoulen JH, Peters JB, Janssen DJA et al. Severe fatigue is highly prevalent in patients with IPF or Sarcoidosis. J Clin Med. 2020;9(4).","DOI":"10.3390\/jcm9041178"},{"issue":"Pt 3","key":"2997_CR138","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1348\/1359107041557048","volume":"9","author":"J De Vries","year":"2004","unstructured":"De Vries J, Michielsen H, Van Heck GL, Drent M. Measuring fatigue in sarcoidosis: the fatigue Assessment Scale (FAS). Br J Health Psychol. 2004;9(Pt 3):279\u201391.","journal-title":"Br J Health Psychol"},{"key":"2997_CR139","doi-asserted-by":"crossref","unstructured":"Dowman L, Hill CJ, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev. 2014(10):CD006322.","DOI":"10.1002\/14651858.CD006322.pub3"},{"issue":"5","key":"2997_CR140","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1159\/000486964","volume":"95","author":"H Lingner","year":"2018","unstructured":"Lingner H, Buhr-Schinner H, Hummel S, van der Meyden J, Grosshennig A, Nowik D, Schultz K. Short-term effects of a Multimodal 3-Week Inpatient Pulmonary Rehabilitation Programme for patients with sarcoidosis: the ProKaSaRe Study. Respiration. 2018;95(5):343\u201353.","journal-title":"Respiration"},{"issue":"3","key":"2997_CR141","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S2213-2600(22)00387-3","volume":"11","author":"V Kahlmann","year":"2023","unstructured":"Kahlmann V, Moor CC, van Helmondt SJ, Mostard RLM, van der Lee ML, Grutters JC, et al. Online mindfulness-based cognitive therapy for fatigue in patients with sarcoidosis (TIRED): a randomised controlled trial. Lancet Respir Med. 2023;11(3):265\u201372.","journal-title":"Lancet Respir Med"},{"issue":"5","key":"2997_CR142","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1378\/chest.07-2952","volume":"133","author":"EE Lower","year":"2008","unstructured":"Lower EE, Harman S, Baughman RP. Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue. Chest. 2008;133(5):1189\u201395.","journal-title":"Chest"},{"issue":"2","key":"2997_CR143","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jpainsymman.2012.02.016","volume":"45","author":"EE Lower","year":"2013","unstructured":"Lower EE, Malhotra A, Surdulescu V, Baughman RP. Armodafinil for sarcoidosis-associated fatigue: a double-blind, placebo-controlled, crossover trial. J Pain Symptom Manage. 2013;45(2):159\u201369.","journal-title":"J Pain Symptom Manage"},{"key":"2997_CR144","doi-asserted-by":"crossref","unstructured":"Atkins C, Jones A, Clark AB, Stockl A, Fordham R, Wilson AM. Feasibility of investigating methylphenidate for the treatment of sarcoidosis-associated fatigue (the FaST-MP study): a double-blind, parallel-arm randomised feasibility trial. BMJ Open Respir Res. 2021;8(1).","DOI":"10.1136\/bmjresp-2020-000814"},{"issue":"9","key":"2997_CR145","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1080\/17476348.2020.1776118","volume":"14","author":"AM Yohannes","year":"2020","unstructured":"Yohannes AM. Depression and anxiety in patients with interstitial lung disease. Expert Rev Respir Med. 2020;14(9):859\u201362.","journal-title":"Expert Rev Respir Med"},{"issue":"3","key":"2997_CR146","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1177\/1479972313493098","volume":"10","author":"AA Akhtar","year":"2013","unstructured":"Akhtar AA, Ali MA, Smith RP. Depression in patients with idiopathic pulmonary fibrosis. Chron Respir Dis. 2013;10(3):127\u201333.","journal-title":"Chron Respir Dis"},{"key":"2997_CR147","doi-asserted-by":"crossref","unstructured":"Faverio P, Bocchino M, Caminati A, Fumagalli A, Gasbarra M, Iovino P et al. Nutrition in patients with idiopathic pulmonary fibrosis: critical issues analysis and future research directions. Nutrients. 2020;12(4).","DOI":"10.3390\/nu12041131"},{"issue":"4","key":"2997_CR148","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1159\/000490355","volume":"96","author":"Y Nakatsuka","year":"2018","unstructured":"Nakatsuka Y, Handa T, Kokosi M, Tanizawa K, Puglisi S, Jacob J, et al. The clinical significance of Body Weight loss in idiopathic pulmonary fibrosis patients. Respiration. 2018;96(4):338\u201347.","journal-title":"Respiration"},{"issue":"3","key":"2997_CR149","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/resp.12941","volume":"22","author":"O Nishiyama","year":"2017","unstructured":"Nishiyama O, Yamazaki R, Sano H, Iwanaga T, Higashimoto Y, Kume H, Tohda Y. Fat-free mass index predicts survival in patients with idiopathic pulmonary fibrosis. Respirology. 2017;22(3):480\u20135.","journal-title":"Respirology"},{"key":"2997_CR150","doi-asserted-by":"crossref","unstructured":"Caminati A, Lonati C, Cassandro R, Elia D, Pelosi G, Torre O et al. Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue. Eur Respir Rev. 2019;28(153).","DOI":"10.1183\/16000617.0044-2019"},{"issue":"4","key":"2997_CR151","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1183\/13993003.02316-2014","volume":"46","author":"G Raghu","year":"2015","unstructured":"Raghu G, Amatto VC, Behr J, Stowasser S. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J. 2015;46(4):1113\u201330.","journal-title":"Eur Respir J"},{"issue":"3","key":"2997_CR152","doi-asserted-by":"publisher","first-page":"e0151425","DOI":"10.1371\/journal.pone.0151425","volume":"11","author":"M Kreuter","year":"2016","unstructured":"Kreuter M, Ehlers-Tenenbaum S, Palmowski K, Bruhwyler J, Oltmanns U, Muley T, et al. Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. PLoS ONE. 2016;11(3):e0151425.","journal-title":"PLoS ONE"},{"issue":"5","key":"2997_CR153","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","volume":"9","author":"J Behr","year":"2021","unstructured":"Behr J, Prasse A, Kreuter M, Johow J, Rabe KF, Bonella F, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9(5):476\u201386.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"2997_CR154","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1164\/rccm.201403-0446OC","volume":"190","author":"TJ Corte","year":"2014","unstructured":"Corte TJ, Keir GJ, Dimopoulos K, Howard L, Corris PA, Parfitt L, et al. Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2014;190(2):208\u201317.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"2997_CR155","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1183\/09031936.00213911","volume":"41","author":"MM Hoeper","year":"2013","unstructured":"Hoeper MM, Halank M, Wilkens H, Gunther A, Weimann G, Gebert I, et al. Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial. Eur Respir J. 2013;41(4):853\u201360.","journal-title":"Eur Respir J"},{"issue":"1","key":"2997_CR156","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1164\/rccm.201011-1874OC","volume":"184","author":"TE King Jr","year":"2011","unstructured":"King TE Jr., Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(1):92\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"2997_CR157","doi-asserted-by":"publisher","first-page":"641","DOI":"10.7326\/0003-4819-158-9-201305070-00003","volume":"158","author":"G Raghu","year":"2013","unstructured":"Raghu G, Behr J, Brown KK, Egan JJ, Kawut SM, Flaherty KR, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013;158(9):641\u20139.","journal-title":"Ann Intern Med"},{"issue":"6","key":"2997_CR158","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1183\/09031936.00104612","volume":"42","author":"G Raghu","year":"2013","unstructured":"Raghu G, Million-Rousseau R, Morganti A, Perchenet L, Behr J, Group MS. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Respir J. 2013;42(6):1622\u201332.","journal-title":"Eur Respir J"},{"issue":"38","key":"2997_CR159","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618\u2013731.","journal-title":"Eur Heart J"},{"key":"2997_CR160","doi-asserted-by":"crossref","unstructured":"Waxman A, Restrepo-Jaramillo R, Thenappan T, Engel P, Bajwa A, Ravichandran A et al. Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study. Eur Respir J. 2023;61(6).","DOI":"10.1183\/13993003.02414-2022"},{"issue":"2","key":"2997_CR161","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.chest.2019.04.114","volume":"156","author":"A Tzouvelekis","year":"2019","unstructured":"Tzouvelekis A, Gomatou G, Bouros E, Trigidou R, Tzilas V, Bouros D. Common pathogenic mechanisms between idiopathic pulmonary fibrosis and Lung Cancer. Chest. 2019;156(2):383\u201391.","journal-title":"Chest"},{"issue":"8","key":"2997_CR162","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1513\/AnnalsATS.201807-481OC","volume":"16","author":"SW Brown","year":"2019","unstructured":"Brown SW, Dobelle M, Padilla M, Agovino M, Wisnivesky JP, Hashim D, Boffetta P. Idiopathic pulmonary fibrosis and Lung Cancer. A systematic review and Meta-analysis. Ann Am Thorac Soc. 2019;16(8):1041\u201351.","journal-title":"Ann Am Thorac Soc"},{"issue":"5","key":"2997_CR163","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/j.athoracsur.2011.06.055","volume":"92","author":"Y Saito","year":"2011","unstructured":"Saito Y, Kawai Y, Takahashi N, Ikeya T, Murai K, Kawabata Y, Hoshi E. Survival after surgery for pathologic stage IA non-small cell lung cancer associated with idiopathic pulmonary fibrosis. Ann Thorac Surg. 2011;92(5):1812\u20137.","journal-title":"Ann Thorac Surg"},{"issue":"6","key":"2997_CR164","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1136\/thoraxjnl-2015-207439","volume":"71","author":"Z Ahmadi","year":"2016","unstructured":"Ahmadi Z, Wysham NG, Lundstr\u00f6m S, Janson C, Currow DC, Ekstr\u00f6m M. End-of-life care in oxygen-dependent ILD compared with lung cancer: a national population-based study. Thorax. 2016;71(6):510\u20136.","journal-title":"Thorax"},{"issue":"3","key":"2997_CR165","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1136\/thoraxjnl-2020-215917","volume":"76","author":"T Koyauchi","year":"2021","unstructured":"Koyauchi T, Suzuki Y, Sato K, Hozumi H, Karayama M, Furuhashi K, et al. Quality of dying and death in patients with interstitial lung disease compared with lung cancer: an observational study. Thorax. 2021;76(3):248\u201355.","journal-title":"Thorax"},{"issue":"2","key":"2997_CR166","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1378\/chest.14-1127","volume":"147","author":"KO Lindell","year":"2015","unstructured":"Lindell KO, Liang Z, Hoffman LA, Rosenzweig MQ, Saul MI, Pilewski JM, et al. Palliative care and location of death in decedents with idiopathic pulmonary fibrosis. Chest. 2015;147(2):423\u20139.","journal-title":"Chest"},{"issue":"12","key":"2997_CR167","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1089\/jpm.2015.0177","volume":"18","author":"F Burge","year":"2015","unstructured":"Burge F, Lawson B, Johnston G, Asada Y, McIntyre PF, Flowerdew G. Preferred and actual location of death: what factors enable a Preferred Home Death? J Palliat Med. 2015;18(12):1054\u20139.","journal-title":"J Palliat Med"},{"issue":"2","key":"2997_CR168","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/1049909120924995","volume":"38","author":"N Archibald","year":"2020","unstructured":"Archibald N, Bakal JA, Richman-Eisenstat J, Kalluri M. Early Integrated Palliative Care Bundle impacts location of death in interstitial lung disease: a pilot retrospective study. Am J Hospice Palliat Medicine\u00ae. 2020;38(2):104\u201313.","journal-title":"Am J Hospice Palliat Medicine\u00ae"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-024-02997-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-024-02997-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-024-02997-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T19:03:46Z","timestamp":1730487826000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-024-02997-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":168,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2997"],"URL":"https:\/\/doi.org\/10.1186\/s12931-024-02997-7","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]},"assertion":[{"value":"10 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"D.E.H. is paid a salary by the Netherlands Organisation for Health Research and Development. T.M. declares no competing interests. C.C.M.: Grants and fees from Boehringer-Ingelheim and Astra-Zeneca-Daiichi Sankyo paid to institution. L.R.: Grants and fees from Boehringer Ingelheim, Zambon, Roche, FibroGen, Nitto, Pliant Therapeutics, BMS, and CSL Behring.\u00a0M.S.W.:\u00a0Grants and fees from The Netherlands Organisation for Health Research and Development, The Dutch Lung Foundation, The Dutch Pulmonary Fibrosis organization, Sarcoidosis.nl, Boehringer Ingelheim, Hoffman la Roche, AstraZeneca-Daiichi, Bristol Myers Squibb, Galapagos, Alecto, GSK, Horizon therapeutics, Kinevant sciences, Molecure, Nerre Therapeutics, Novartis, PureTech Health, Thyron, Trevi,\u00a0Vicore, and CSL Behring paid to institution. Y.W.: Grants and fees from Boehringer Ingelheim, Nippon Boehringer Ingelheim, Chugai, Taiho, Thermofisher Diagnostics, Glaxo SmithKline, Kyorin, Astra Zeneca, Sanofi, Nippon Shinyaku, and Novo Nordisk.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"395"}}